Skip to main content
Premium Trial:

Request an Annual Quote

Verisante Raises $310,000 in Private Placement

Premium

Verisante Technology said it has raised C$350,000 ($310,000) in a non-brokered private placement.

The placement, from unidentified Chinese investors, consisted of 2.5 million common shares at a price of C$.14 per share.

With this placement, the Chinese group has now invested C$650,000 of the C$2.15 million they have agreed to put into Verisante over the next 24 months as per an agreement between the two parties.

The money will be used for working capital requirements, Verisante said.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.